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Poster Session-I 39status (P5 0.1); and extra nodal involvement (p5 0.4).We identified
an inverse correlation between day 15 IL-15 and day 15 NK cell re-
covery (r 5 20.5, p\ 0.0001). Patients with a day15 IL-15 # 9.5
pg/ml experienced higher numbers of NK cells compared with those
with a day 15 IL-15. 9.5 pg/ml [median 142 cells/ml (range: 10–416
cells/ml) versus median 57.5 cells/ml (range: 28–999 cells/ml), p\
0.001, respectively]. Using logistic regression models, univariately
day 15 IL-15 was a predictor for NK cell recovery (p\0.0003) and
multivariately day 15 IL-15 remained a predictor for NK cell recov-
ery (p\0.0004). To our knowledge, this is the first study showing an
associationbetweenday 15 IL-15 andNKcell recovery inASCT.We
showed an inverse relationship between day 15 IL-15 and NK cell
numbers consistent with a homeostatic association. The data pre-
sented here suggest that day 15 NK cell recovery might be driven
by the cytokine milieu post-ASCT.95
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Relapse of NHL is a problem after ASCT. Early after ASCT, the
immune system is not as active, which can impair the ability to erad-
icate residual disease. The addition of immunotherapy may decrease
the incidence of relapse and prolong survival. In a phase I/II trial at
FHCRC, the immune-modulator IL-2 increased NK and LAK ac-
tivity in vitro. Since Rituxan lyses CD201 cells by ADCC, adding
Rituxan to IL-2 should boost its effectiveness. Twenty patients
with CD201NHL received ASCT followed by Rituxan/IL-2 ther-
apy. The pathology at ASCT included: follicular small/large cleaved
(n5 2), diffuse large/T cell rich B cell (n5 8), mantle cell (n5 4) and
transformed from indolent to diffuse (n 5 6). The disease status at
ASCT was refractory (n 5 8), relapse 1 (PR) (n 5 1), remission 1
(n 5 3), remission 2 (n5 6) and relapse/untreated (n 5 1). Previous
Rituxan use was (n 5 9). The median age of patients was 46 years
(range 31–70). The median time to initiation of therapy was 79
days post ASCT (range 49–100). The treatment schema was: IL-2
0.6  106 IU/m2/day sc times 12 weeks, followed by 1.4  106 IU/
m2 sc 3 times/week for an additional 12 weeks (total of 24 weeks of
IL-2 therapy). Rituxan was given iv at 375 mg/m2 for a total of 4
doses: beginning one day prior to starting IL-2, then between days
25–30, 50–55 and 75–80 post beginning IL-2. NCI Common Tox-
icity Criteria were used to evaluate adverse events. Most common
grade 3/4 toxicities were neutropenia (n 5 9), pneumonia (n 5 2)
at 7–8 weeks of therapy, hypothyroidism (n 5 1), hypokalemia
(n 5 1) and pulmonary dysfunction (decreased DLCO) (n 5 1) at
5 weeks of therapy. Neutropenia responded to G-CSF. There
were 11 infections: pneumonia (influenza, n5 1, and pneumococcus
strept, n 5 1), oral thrush (n 5 2), herpes simplex (n 5 1), urinary
tract (n5 1), zoster (n5 1) and upper respiratory (n5 4).Most com-
mon side effects were fatigue, erythema/induration/discomfort at
IL-2 injection sites and flu-like symptoms. Seven patients stopped
therapy due to subdural hematoma/progression of NHL (n 5 1),
pneumonia (n 5 2), decreased DLCO (n 5 1) or at own/physician’s
choice without grade 3/4 toxicity at 9, 13, 14.5 weeks after complet-
ing Rituxan (n5 3). With a median follow-up of 76.5 months (range
43–93), 18 patients (90%) are alive, 17 patients (85%) are alive inCR.
Two patients died of relapsed disease. The combination of IL-2/Rit-
uxan after ASCT continues to show a high and durable response rate
in CD201 NHL patients.96
AUTOLOGOUS HEMATOPOEITIC STEM CELL TRANSPLANTATION (HSCT)
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST OR SEC-
OND REMISSION
Naqvi, H., John, V., Devoe, C., Kiner, B., Kolitz, J., Allen, S.,
Gissinger, D., Cannon, M., Fitzgerald, E., Klocke, J., Bayer, R.-L. North
Shore University Hospital, Manhasset, NYWe report 40 patients (pts) with AMLwho underwent autologous
HSCT in first (CR1) or second (CR2) remission from 2002 to 2007.
Twenty one were male and nineteen were female with a mean age of
52.8 (range 35–66) years. Patients enrolled in clinical trials are not
included in this analysis. Using CALGB (Byrd) criteria, 6 had favor-
able cytogenetic risk (all in CR2), 26 had intermediate risk, including
22 with normal karyotypes (20 in CR1 and 2 in CR2), and 8 had un-
favorable cytogenetics (7 in CR1 and 1 in CR2), including two pa-
tients with t(9;22). One pt had Ph1 AML and one CML with
myeloid blast crisis. One patient had AML transformed frommyelo-
dysplastic syndrome (MDS). Four patients had AMLwith multi-lin-
eage dysplasia (MLD). Nine patients were in CR2. Thirty-five
patients had intensification / mobilization with high dose VP16/
ARAC, four with high dose ARAC and one patient had a bone mar-
row harvest. Thirty-six patients received Busulfan (0.8mg/kg x 16
doses) and VP-16 (60mg/kg) as their preparative regimen. Four re-
ceived Busulfan (0.8 mg/kg x 16 doses) and Cytoxan (120 mg/kg).
One hundred day transplant related mortality was 2.5%.Mean over-
all survival was 20.9 months. Mean disease free survival was 36.7
months with a range of 10–76 months. One year overall survival
was 63%, with a one year disease free survival of 40%. Four of six
pts with favorable cytogenetics are alive in CR more than 24 months
after autologous transplant. Two patients with t(9;22) are on imati-
nib maintenance in CR 12 and 42 months post transplant. One pa-
tient with APL developed a secondary MDS with a monosomy 7.
No patients with prior MDS or MLD were alive after 12 months.
Five patients who relapsed after autologous HSCT went on to re-
ceive reduced intensity allogeneic transplantation with a 100 day
mortality of 0%. We conclude that autologous HSCT should be
considered an effective and safe post-remission consolidation ther-
apy for pts with intermediate risk AML in CR1 and for pts with fa-
vorable cytogenetics in CR2. Patients with MLD and prior MDS
do poorly. Prior autologous HSCT does not increase the 100 day
mortality with reduced intensity allogeneic transplantation. Further
studies are necessary, continuing to focus on risk-adapted therapy
and assessing quality of life endpoints.97
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Many tests are used to determine patient physical fitness for
blood and marrow transplant (BMT). BMT patients usually re-
ceive prior toxic therapies that result in deconditioning pre-
BMT. One measure of physical fitness is the ability to reach
a target heart rate without a significant decrease in oxygen satu-
ration (O2sat) during exercise. We retrospectively analyzed 183
consecutive first adult ($18 years) autologous (n 5 95) or alloge-
neic (n 5 88) BMT pts treated from 7/05 to 4/08 to analyze
overall survival (OS) in relation to a pre-BMT physical therapy
evaluation, along with standard cardiac and pulmonary function
tests. The physical therapy evaluation included Karnofsky perfor-
mance score (KPS), resting and post-exercise heart rate (HR) and
O2sat, ability to reach target HR and ability to complete an ex-
ercise test consisting of 50 step-ups or walking on a treadmill.
Median age was 53 yrs (range 18–71), male 61%, White 93%,
leukemia (n 5 65), lymphoma (n 5 68), myeloma (n 5 24), he-
matologic disorders (n 5 23), and solid tumors (n 5 3), donors
were autologous (n 5 95), related (n 5 37), or unrelated (n 5
51). Median follow-up in survivors was 1 yr (range 0.1–2.9).
162 (89%) were able to complete the exercise test; reasons for
not completing the test included fatigue and rapid heart rate.
37% of autologous and 21% of allogeneic BMT patients who
completed the exercise test reached their target HR. Medians
(ranges) were: resting HR 87.5 (56–150) and O2sat 98 (89–
100), post-exercise HR 126.5 (72–186) and O2sat 98 (88–100),
left ventricular ejection fraction (LVEF) 61 (50–80), corrected
carbon monoxide diffusing capacity (DLCOcorr) 80 (35–126),
forced expiratory volume in one second (FEV1) 95 (35–146).
Multivariate analysis used a Cox proportional hazards model
with backward elimination with the following potential
